HIV Studies For Naive And Experience Patients
FOR HIV NEVER TREATED BEFORE
Protocol Title: ViiV Healthcare / “A Phase III, randomised, double-blind, multicentre, parallel- group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults”
ClinicalTrials.gov Identifier: NCT02831673
Protocol Title: A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-Naive Adults
ClinicalTrials.gov Identifier: NCT03045861
Protocol Title: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability ofLong-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor
Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
ClinicalTrials.gov Identifier: NCT02938520
PATIENTS ON HIV THERAPY
Protocol Title: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed.
ClinicalTrials.gov Identifier: NCT03446573
Protocol Title: A Phase IIIb, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed
ClinicalTrials.gov Identifier: NCT02105987
Protocol Title: Prior Experience with Dolutegravir-based Two-drug Regimen and Outcomes (PEDTRO): Motivation behind the use of DTG-based 2DRs for Treatment of HIV in the United States.
Protocol Title: A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 and Prevnar 13™ Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults 18 Years of Age or Older Infected with HIV.
ClinicalTrials.gov Identifier: NCT02225587